David L. Johnson

David L. Johnson

Chief Commercial Officer

Mr. Johnson joined GBT in March 2018 as chief commercial officer. He is responsible for creating and leading the company’s commercial operations, including building and leading sales, marketing, business analytics and market access. Prior to GBT, Mr. Johnson spent 15 years at Gilead Sciences, Inc., in roles of increasing responsibility. Most recently, he served as vice president, sales and marketing, Liver Disease Business Unit, where he was responsible for the company’s liver disease franchises. He was instrumental in the commercial launches of the hepatitis C treatments Sovaldi®, Harvoni®, Epclusa® and Vosevi® and the hepatitis B treatment Vemlidy®. Prior to that position, he was vice president, sales and marketing, for Gilead’s Antiviral Business Unit, where he launched the HIV treatments Complera® and Stribild®. Prior to joining Gilead, Mr. Johnson had an 11-year tenure at GlaxoSmithKline, where he held various positions in sales, product marketing, business development, global commercial strategy and portfolio development. He received a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.